Current Assets
Allowance for Doubtful Accounts Receivable (Current)
Medtronic Allowance for Doubtful Accounts Receivable (Current) increased by 3.5% to $207M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.5%, from $204M to $207M. Over 4 years (FY 2021 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -4.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2015
Last reportedQ3 2026Feb 24, 2026
Metric ID:
allowance_for_doubtful_accounts_receivable_currentHistorical Data
20 periods
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $241M | $257M | $255M | $253M | $230M | $219M | $203M | $207M | $176M | $190M | $177M | $180M | $173M | $170M | $195M | $204M | $199M | $204M | $200M | $207M |
| QoQ Change | — | +6.6% | -0.8% | -0.8% | -9.1% | -4.8% | -7.3% | +2.0% | -15.0% | +8.0% | -6.8% | +1.7% | -3.9% | -1.7% | +14.7% | +4.6% | -2.5% | +2.5% | -2.0% | +3.5% |
| YoY Change | — | — | — | — | -4.6% | -14.8% | -20.4% | -18.2% | -23.5% | -13.2% | -12.8% | -13.0% | -1.7% | -10.5% | +10.2% | +13.3% | +15.0% | +20.0% | +2.6% | +1.5% |
Range$170M – $257M
CAGR-3.2%
Avg YoY Growth-4.4%
Median YoY Growth-7.5%
Allowance for Doubtful Accounts Receivable (Current) at Other Companies
Frequently Asked Questions
- What is Medtronic's allowance for doubtful accounts receivable (current)?
- Medtronic (MDT) reported allowance for doubtful accounts receivable (current) of $207M in Q4 2025.
- How has Medtronic's allowance for doubtful accounts receivable (current) changed year-over-year?
- Medtronic's allowance for doubtful accounts receivable (current) increased by 1.5% year-over-year, from $204M to $207M.
- What is the long-term trend for Medtronic's allowance for doubtful accounts receivable (current)?
- Over 4 years (2021 to 2025), Medtronic's allowance for doubtful accounts receivable (current) has grown at a -4.7% compound annual growth rate (CAGR), from $241M to $199M.